Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585540 · ClinicalTrials.gov registry record · Phase 3
A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population
A Phase 3 study of Post Operative Nausea and Vomiting, sponsored by Benaroya Research Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT06585540 is a Phase 3 study of Post Operative Nausea and Vomiting that is actively recruiting participants, run by Benaroya Research Institute. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06585540, a Phase 3 study of Post Operative Nausea and Vomiting, is actively recruiting participants, sponsored by Benaroya Research Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the effectiveness of Amisulpride to treat Post Operative Nausea and Vomiting (PONV) and to assess the effectiveness of Amisulpride to prevent PONV following bariatric surgery.
Conditions Studied
Interventions
- DRUG Amisulpride IV Prevention
- DRUG Amisulpride IV Treatment
- DRUG Placebo Preventative
- DRUG Placebo Treatment
Study Locations (1)
Washington
- Virginia Mason Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-09-13 |
| Est. Completion | 2026-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06585540
The ClinicalTrials.gov registry entry for NCT06585540 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Operative Nausea and Vomiting appearing as the primary indexed condition, and to 4 interventions - of which Amisulpride IV Prevention is the first listed.
NCT06585540 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT06585540 about?
NCT06585540 is a clinical study titled "A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population". To assess the effectiveness of Amisulpride to treat Post Operative Nausea and Vomiting (PONV) and to assess the effectiveness of Amisulpride to prevent PONV following bariatric surgery.
What is the current status of trial NCT06585540?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2024-09-13. Estimated completion is 2026-01.
What conditions does trial NCT06585540 study?
This clinical trial studies the following conditions: Post Operative Nausea and Vomiting.
What interventions are being tested in trial NCT06585540?
The interventions under investigation include: Amisulpride IV Prevention (DRUG), Amisulpride IV Treatment (DRUG), Placebo Preventative (DRUG), Placebo Treatment (DRUG).
Who is sponsoring clinical trial NCT06585540?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585540 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.